Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma

Shen, Qiu-Dan; Wang, Li; Zhu, Hua-Yuan; Liang, Jin-Hua; Xia, Yi; Wu, Jia-Zhu; Fan, Lei; Li, Jian-Yong; Xu, Wei

doi:10.7150/jca.47031



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2021; 12(1):163-169. doi:10.7150/jca.47031 This issue Cite

Research Paper

Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma

Qiu-Dan Shen^1*, Li Wang^1*, Hua-Yuan Zhu^1,2, Jin-Hua Liang¹, Yi Xia^1,2, Jia-Zhu Wu¹, Lei Fan^1,2, Jian-Yong Li^1,2✉, Wei Xu^1,2✉

1. Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China.
2. Pukou CLL Center, Nanjing 210000, China.
*These authors contributed equally to this work.

Citation:

Shen QD, Wang L, Zhu HY, Liang JH, Xia Y, Wu JZ, Fan L, Li JY, Xu W. Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma. J Cancer 2021; 12(1):163-169. doi:10.7150/jca.47031. https://www.jcancer.org/v12p0163.htm

Other styles

Abstract

Background Outcomes of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL) remain poor. The objective of this study was to evaluate the efficacy and safety of gemcitabine, oxaliplatin and dexamethasone (GemDOx) with or without rituximab as salvage therapy in patients with relapsed or refractory DLBCL and PTCL.

Materials and Methods: We retrospectively reviewed patients with relapsed or refractory DLBCL and PTCL receiving GemDOx as salvage therapy between Jul 1, 2011, and Aug 31, 2017.

Results: Thirty-three (57.9%) patients with relapsed or refractory DLBCL and 24 (42.1%) with PTCL were included in this study. The median age was 57 years (inter-quartile range 46-67). The overall response rate (ORR) in DLBCL was 48.5% with 27.3% of complete remission (CR), and the 2-year progression-free survival (PFS) and 2-year overall survival (OS) was 21% and 44%. In patients with PTCL, ORR was 50.0% with CR rate of 29.2%; the 2-year PFS and 2-year OS was 28% and 49%, respectively. Common grade 3-4 hematological adverse events were thrombocytopenia (26.3%), anemia (15.7%) and neutropenia (15.7%).

Conclusion: With acceptable efficacy and good tolerability, GemDOx might be a new therapeutic option for relapsed or refractory DLBCL and PTCL.

Keywords: gemcitabine, oxaliplatin and dexamethasone, relapsed or refractory diffuse large B-cell lymphoma, peripheral T-cell lymphoma

Citation styles

APA

Shen, Q.D., Wang, L., Zhu, H.Y., Liang, J.H., Xia, Y., Wu, J.Z., Fan, L., Li, J.Y., Xu, W. (2021). Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma. Journal of Cancer, 12(1), 163-169. https://doi.org/10.7150/jca.47031.

ACS

Shen, Q.D.; Wang, L.; Zhu, H.Y.; Liang, J.H.; Xia, Y.; Wu, J.Z.; Fan, L.; Li, J.Y.; Xu, W. Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma. J. Cancer 2021, 12 (1), 163-169. DOI: 10.7150/jca.47031.

NLM

CSE

Shen QD, Wang L, Zhu HY, Liang JH, Xia Y, Wu JZ, Fan L, Li JY, Xu W. 2021. Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma. J Cancer. 12(1):163-169.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.